Jacques Turgeon

Summary

Country: Canada

Publications

  1. ncbi The pharmacokinetics of ezetimibe
    Chantale Simard
    ,
    Can J Clin Pharmacol 10:13A-20A. 2003
  2. ncbi Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan
    Simon de Denus
    Faculty of Pharmacy, University of Montreal, Montreal Heart Institute, Montreal, QC, Canada
    Ann Pharmacother 42:925-32. 2008
  3. ncbi Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination
    Frederique Fenneteau
    Faculte de Pharmacie, Universite de Montreal, Montreal, Quebec, Canada
    Theor Biol Med Model 6:2. 2009
  4. ncbi Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism
    Jacques Turgeon
    , , , Que
    CMAJ 174:1729. 2006
  5. ncbi Increased risk of myocardial infarction associated with angiotensin-converting enzyme gene polymorphism is age dependent
    Bettina A Hamelin
    Quebec Heart Institute, Quebec, Canada
    J Clin Pharmacol 51:1286-92. 2011
  6. ncbi Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humans
    Veronique Michaud
    Faculty of Pharmacy, Universite de Montreal, Montreal, Quebec, Canada
    Ther Drug Monit 28:779-83. 2006
  7. ncbi Ten renin-angiotensin system-related gene polymorphisms in maximally treated Canadian Caucasian patients with heart failure
    Marcin Zakrzewski-Jakubiak
    Universite de Montreal, Montreal, Canada
    Br J Clin Pharmacol 65:742-51. 2008
  8. ncbi A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease
    Marie Lordkipanidzé
    Faculty of Pharmacy, Universite de Montreal, Montreal, Quebec, Canada
    Eur Heart J 28:1702-8. 2007
  9. ncbi The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension
    Jean Lefebvre
    Hypertension Research Unit, CHUL Research Center, Faculty of Pharmacy, Laval University, Quebec, Canada
    Br J Clin Pharmacol 63:575-82. 2007
  10. ncbi Drug-induced long QT syndrome in women: review of current evidence and remaining gaps
    Raymond Hreiche
    Faculty of Pharmacy, Université de Montréal and Research Center, CHUM, Montreal, Quebec, Canada
    Gend Med 5:124-35. 2008

Collaborators

  • Chantal Pharand
  • Frederique Fenneteau
  • Marcin Zakrzewski-Jakubiak
  • Line Labbe
  • Simon de Denus
  • Bettina A Hamelin
  • Raymond Hreiche
  • Michel White
  • Francois Belanger
  • Marie Pierre Dube
  • N Michelle Robitaille
  • Jean Lefebvre
  • Marie Lordkipanidzé
  • Veronique Michaud
  • Marcel Gilbert
  • Chantale Simard
  • Peter Bogaty
  • Joel Lavoie
  • Marie Helene Leblanc
  • Lucette Whittom
  • Anique Ducharme
  • Pierre Morissette
  • Rhian M Touyz
  • Denis Gossard
  • Normand Racine
  • Serge Lepage
  • Jean G Diodati
  • Erick Schampaert
  • Yves Lacourciere
  • Paul Poirier
  • Luc Poirier
  • Donald A Palisaitis
  • Mohamad Samer Mouksassi
  • Odette Grech-Bélanger
  • Liliane Ayotte Ferron
  • Pierre Maxime Bélanger
  • Gilles O'Hara
  • Christophe Lefez
  • Diane Potvin

Detail Information

Publications11

  1. ncbi The pharmacokinetics of ezetimibe
    Chantale Simard
    ,
    Can J Clin Pharmacol 10:13A-20A. 2003
    ..5- to 2-fold. So far, no drug interaction study has been associated with major changes in either the pharmokinetics of ezetimibe or coadministered drugs...
  2. ncbi Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan
    Simon de Denus
    Faculty of Pharmacy, University of Montreal, Montreal Heart Institute, Montreal, QC, Canada
    Ann Pharmacother 42:925-32. 2008
    ..It is currently impossible to determine which patient will benefit from the addition of an ARB...
  3. ncbi Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination
    Frederique Fenneteau
    Faculte de Pharmacie, Universite de Montreal, Montreal, Quebec, Canada
    Theor Biol Med Model 6:2. 2009
    ..This work aims to improve our understanding of the impact of P-gp activity modulation on tissue distribution of P-gp substrate...
  4. ncbi Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism
    Jacques Turgeon
    , , , Que
    CMAJ 174:1729. 2006
  5. ncbi Increased risk of myocardial infarction associated with angiotensin-converting enzyme gene polymorphism is age dependent
    Bettina A Hamelin
    Quebec Heart Institute, Quebec, Canada
    J Clin Pharmacol 51:1286-92. 2011
    ..05). Similar observations were obtained versus the healthy elderly men (P < .05). The ACE-I/D polymorphism seems to be a genetic risk factor for MI in young men and becomes an important modulator of MI risk at a young age...
  6. ncbi Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humans
    Veronique Michaud
    Faculty of Pharmacy, Universite de Montreal, Montreal, Quebec, Canada
    Ther Drug Monit 28:779-83. 2006
    ..Caffeine has intrinsic proarrhythmic effects; thus, its coadministration with an antiarrhythmic agent such as propafenone should be used with caution, especially in patients with poor CYP2D6 activity...
  7. ncbi Ten renin-angiotensin system-related gene polymorphisms in maximally treated Canadian Caucasian patients with heart failure
    Marcin Zakrzewski-Jakubiak
    Universite de Montreal, Montreal, Canada
    Br J Clin Pharmacol 65:742-51. 2008
    ..It is also acknowledged that the genotype frequency of certain gene polymorphisms varies across different ethnic groups and that a difference in gene polymorphism frequencies between healthy and heart failure patients seems to exist...
  8. ncbi A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease
    Marie Lordkipanidzé
    Faculty of Pharmacy, Universite de Montreal, Montreal, Quebec, Canada
    Eur Heart J 28:1702-8. 2007
    ..We sought to compare the results obtained from six major platelet function tests in the assessment of the prevalence of aspirin resistance in patients with stable coronary artery disease...
  9. ncbi The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension
    Jean Lefebvre
    Hypertension Research Unit, CHUL Research Center, Faculty of Pharmacy, Laval University, Quebec, Canada
    Br J Clin Pharmacol 63:575-82. 2007
    ..The metabolism of the third-generation beta(1)-receptor antagonist nebivolol has been shown to be highly dependent on cytochrome P450 2D6 enzymatic activity in preclinical studies...
  10. ncbi Drug-induced long QT syndrome in women: review of current evidence and remaining gaps
    Raymond Hreiche
    Faculty of Pharmacy, Université de Montréal and Research Center, CHUM, Montreal, Quebec, Canada
    Gend Med 5:124-35. 2008
    ..This major cardiac adverse effect may lead to malignant polymorphic ventricular tachycardias, termed torsades de pointes, which may degenerate into ventricular fibrillation and cause sudden death...
  11. ncbi Effects of ciprofloxacin on the stereoselective disposition of mexiletine in man
    Line Labbe
    Quebec Heart Institute, Hopital Laval, Ste Foy, Quebec G1V 4G5, Canada
    Ther Drug Monit 26:492-8. 2004
    ..Nevertheless, results obtained in this study suggest that no major drug interaction is to be expected during the concomitant administration of ciprofloxacin and mexiletine in patients...